PFIZER has agreed to pay
US$490.9 million to resolve claims
relating to illegal marketing of
kidney transplant drug Rapamune
(sirolimus) which it acquired when
it took over Wyeth.
According to the US Department
of Justice, Wyeth trained its
sales staff to promote Rapamune
for unapproved uses between
1998 and 2009, as well as paying
bonuses to encourage these sales.
The DoJ said it was a “systemic,
corporate effort to seek profit over
safety”.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.